Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21,244 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC).
Chen G, Feng J, Zhou C, Wu YL, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu CP, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Chen G, et al. Among authors: zhou c, zhou s. Ann Oncol. 2013 Jun;24(6):1615-22. doi: 10.1093/annonc/mdt012. Epub 2013 Mar 1. Ann Oncol. 2013. PMID: 23456778 Free article. Clinical Trial.
Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S, Lu S, Zhang L, Hu C, Hu C, Luo Y, Chen L, Ye M, Huang J, Zhi X, Zhang Y, Xiu Q, Ma J, Zhang L, You C. Zhou C, et al. Among authors: zhou s. Ann Oncol. 2015 Sep;26(9):1877-1883. doi: 10.1093/annonc/mdv276. Epub 2015 Jul 3. Ann Oncol. 2015. PMID: 26141208 Free article. Clinical Trial.
First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study.
Wu YL, Zhou C, Liam CK, Wu G, Liu X, Zhong Z, Lu S, Cheng Y, Han B, Chen L, Huang C, Qin S, Zhu Y, Pan H, Liang H, Li E, Jiang G, How SH, Fernando MCL, Zhang Y, Xia F, Zuo Y. Wu YL, et al. Among authors: zhou c. Ann Oncol. 2015 Sep;26(9):1883-1889. doi: 10.1093/annonc/mdv270. Epub 2015 Jun 23. Ann Oncol. 2015. PMID: 26105600 Free article. Clinical Trial.
Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-Lung 3 and 6 trials.
Yang JC, Sequist LV, Zhou C, Schuler M, Geater SL, Mok T, Hu CP, Yamamoto N, Feng J, O'Byrne K, Lu S, Hirsh V, Huang Y, Sebastian M, Okamoto I, Dickgreber N, Shah R, Märten A, Massey D, Wind S, Wu YL. Yang JC, et al. Among authors: zhou c. Ann Oncol. 2016 Nov;27(11):2103-2110. doi: 10.1093/annonc/mdw322. Epub 2016 Sep 6. Ann Oncol. 2016. PMID: 27601237 Free article. Clinical Trial.
Combined Measurement of the Higgs Boson Mass in pp Collisions at sqrt[s]=7 and 8 TeV with the ATLAS and CMS Experiments.
Aad G, Abbott B, Abdallah J, Abdinov O, Aben R, Abolins M, AbouZeid OS, Abramowicz H, Abreu H, Abreu R, Abulaiti Y, Acharya BS, Adamczyk L, Adams DL, Adelman J, Adomeit S, Adye T, Affolder AA, Agatonovic-Jovin T, Aguilar-Saavedra JA, Ahlen SP, Ahmadov F, Aielli G, Akerstedt H, Åkesson TP, Akimoto G, Akimov AV, Alberghi GL, Albert J, Albrand S, Alconada Verzini MJ, Aleksa M, Aleksandrov IN, Alexa C, Alexander G, Alexopoulos T, Alhroob M, Alimonti G, Alio L, Alison J, Alkire SP, Allbrooke BM, Allport PP, Aloisio A, Alonso A, Alonso F, Alpigiani C, Altheimer A, Alvarez Gonzalez B, Álvarez Piqueras D, Alviggi MG, Amadio BT, Amako K, Amaral Coutinho Y, Amelung C, Amidei D, Amor Dos Santos SP, Amorim A, Amoroso S, Amram N, Amundsen G, Anastopoulos C, Ancu LS, Andari N, Andeen T, Anders CF, Anders G, Anders JK, Anderson KJ, Andreazza A, Andrei V, Angelidakis S, Angelozzi I, Anger P, Angerami A, Anghinolfi F, Anisenkov AV, Anjos N, Annovi A, Antonelli M, Antonov A, Antos J, Anulli F, Aoki M, Aperio Bella L, Arabidze G, Arai Y, Araque JP, Arce AT, Arduh FA, Arguin JF, Argyropoulos S, Arik M, Armbruster AJ, Arnaez O, Arnal V, Arnold H, Arratia M, Arslan O, Artamonov A, Artoni G, Asai S, Asb… See abstract for full author list ➔ Aad G, et al. Among authors: zhou b, zhou c, zhou l, zhou n. Phys Rev Lett. 2015 May 15;114(19):191803. doi: 10.1103/PhysRevLett.114.191803. Epub 2015 May 14. Phys Rev Lett. 2015. PMID: 26024162 Free article.
Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial.
Schuler M, Yang JC, Park K, Kim JH, Bennouna J, Chen YM, Chouaid C, De Marinis F, Feng JF, Grossi F, Kim DW, Liu X, Lu S, Strausz J, Vinnyk Y, Wiewrodt R, Zhou C, Wang B, Chand VK, Planchard D; LUX-Lung 5 Investigators. Schuler M, et al. Among authors: zhou c. Ann Oncol. 2016 Mar;27(3):417-23. doi: 10.1093/annonc/mdv597. Epub 2015 Dec 8. Ann Oncol. 2016. PMID: 26646759 Free PMC article. Clinical Trial.
21,244 results
You have reached the last available page of results. Please see the User Guide for more information.